Overview

Comparing of the Pharmacokinetics, Immunogenicity and Safety of MV088 and Prolia® in Healthy Adults.

Status:
Not yet recruiting

Trial end date:
2021-10-18

Target enrollment:

Participant gender:

Summary

A Randomized, Double-blind and Parallel Group Study to Compare the Pharmacokinetics, Immunogenicity and Safety of MV088 and Prolia® in Healthy Adults.

Phase:

Phase 1

Details

Lead Sponsor:

Kunming Pharmaceuticals, Inc.

Treatments:

Denosumab